Newsroom

東京--(BUSINESS WIRE)--(美國商業資訊)-- X 光分析系統全球解決方案合作夥伴暨 Rigaku Holdings Corporation（總部：東京昭島市；執行長：Jun Kawakami；以下簡稱 Rigaku）集團旗下公司 Rigaku Corporation，已於其大阪工廠啟用 Rigaku Solutions Center Osaka (RSC-Osaka)。此新設施集中並擴展支援半導體量測系統現場服務工程師的實作訓練，藉此強化 Rigaku 的全球服務能力。 隨著半導體製程逐步邁向更微細的幾何結構、更高的層數與更複雜的 3D 結構，半導體測量系統需要更高的精確度與運作穩定性。X 光分析技術透過高精準度的非破壞性測量，在滿足這些需求方面扮演日益重要的角色。 隨著 Rigaku 半導體量測系統出貨量日益增加，對具備高階技能的現場服務工程師需求亦同步成長。實作訓練對於將儀器效能發揮至極致並將客戶停機時間降至最低極為重要。 為因應此需求，Rigaku 啟用了半導體測量系統專屬訓練設施 RSC-Osaka。大阪工廠內新建的無塵室容納多套半導體測量系統，讓受訓人員能在...

PARIS--(BUSINESS WIRE)--  In line with its strategy to refocus its renewable development on large utility-scale solar and wind farms in order to benefit from economies of scale, TotalEnergies (Paris:TTE) (LSE:TTE) (NYSE:TTE) announces that it has completed the divestment of all its distributed solar assets (around 170 MW), mainly rooftop installations, across 7 European countries (France, Belgium, the Netherlands, Spain, Portugal, the United Kingdom and Luxembourg) to Amarenco and AMPYR Distrib...

PARIS--(BUSINESS WIRE)--In line with its strategy to refocus its renewable development on large utility-scale solar and wind farms in order to benefit from economies of scale, TotalEnergies (Paris:TTE) (LSE:TTE) (NYSE:TTE) announces that it has completed the divestment of all its distributed solar assets (around 170 MW), mainly rooftop installations, across 7 European countries (France, Belgium, the Netherlands, Spain, Portugal, the United Kingdom and Luxembourg) to Amarenco and AMPYR Distribut...

PARIS--(BUSINESS WIRE)--Conformément à sa stratégie de recentrage de son développement renouvelable sur les fermes solaires et éoliennes de grande taille pour tirer parti des effets d’échelle, TotalEnergies (Paris:TTE) (LSE:TTE) (NYSE:TTE) annonce avoir finalisé la cession de l’ensemble de ses actifs solaires distribués (environ 170 MW) majoritairement sur toitures, dans 7 pays d’Europe (France, Belgique, Pays-Bas, Espagne, Portugal, Royaume-Uni, Luxembourg) à Amarenco et à AMPYR Distributed En...

LONDON--(BUSINESS WIRE)--  Commonwealth Bank of Australia Issue of USD 30,000,000.00 Floating Rate Notes due 15 January 2033 Series no 6657 Tranche 1 MTN ISSUE NAME. Our Ref. MS3157 ISIN Code. XS2977999593 TOTAL INTEREST AMT. CURRENCY CODE. USD DAY BASIS. 30/360 BOND BASIS (A001) NUM OF DAYS. 90 INTEREST RATE. 5.23446 PCT VALUE DATE. 15/07/2026 INTEREST PERIOD. 15/04/2026 TO 15/07/2026 USD 392,584.5 POOL FACTOR. N/A...

MALAKOFF, France--(BUSINESS WIRE)--Regulatory News: THERACLION (ISIN : FR0010120402 ; Mnemo : ALTHE), société innovante développant Sonovein®, une plateforme robotique pour la thérapie non invasive des varices par ultrasons focalisés de haute intensité (HIFU), annonce que son Conseil d’Administration, réuni le 8 juillet 2026, a nommé Monsieur Vincent Gardès en qualité de Président du Conseil d’Administration, avec effet immédiat. Administrateur de Theraclion depuis l’Assemblée Générale du 18 ju...

LONDON--(BUSINESS WIRE)--  Santander UK PLC Issue of GBP 1,500,000,000.00 Floating Rate Covered Bonds due Jan 2028 Series 80 Tranche 1 MTN ISSUE NAME. Our Ref. MP2432 ISIN Code. XS2574480708 TOTAL INTEREST AMT. CURRENCY CODE. GBP DAY BASIS. ACTUAL/365 FIXED (A005) NUM OF DAYS. 91 INTEREST RATE. 4.3976 PCT VALUE DATE. 13/07/2026 INTEREST PERIOD. 13/04/2026 TO 13/07/2026 GBP 16,445,819.18 POOL FACTOR. N/A...

MALAKOFF, France--(BUSINESS WIRE)--Regulatory News: THERACLION (ISIN: FR0010120402; Mnemo: ALTHE), an innovative company developing Sonovein®, a robotic platform for non-invasive varicose vein therapy using High-Intensity Focused Ultrasound (HIFU), announces that its Board of Directors, which met on July 8, 2026, has appointed Mr. Vincent Gardès as Chairman of the Board of Directors, with immediate effect. A Director of Theraclion since the General Meeting of June 18, 2026, after having served...

LONDON--(BUSINESS WIRE)--  Pershing Square Holdings, Ltd. Announces Transactions in Own Shares and Weekly Summary of Transactions in Own Shares – 8 July 2026 Pershing Square Holdings, Ltd. (LN:PSH) (LN:PSHD) (“PSH”) today announced that it has purchased, through PSH’s agent, Jefferies International Limited (“Jefferies”), the following number of PSH’s Public Shares of no par value (ISIN Code: GG00BPFJTF46) (the "Shares"): Total Buyback   Ticker/s: PSH (LSE); PSHD (LSE) Date of Purchase: 8 July 2...

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and partner AstraZeneca today announced that the CARDIO-TTRansform Phase 3 trial for eplontersen in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) did not meet the primary efficacy endpoint of the composite outcome of cardiovascular (CV) mortality and recurrent CV clinical events up to Week 140 compared with placebo. In this contemporary patient population treated with standard of care, includin...